戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ck expression of NKG2D ligands recognized by CIK cells.
2                                              CIK cells accumulated and persisted in tumor sites, resu
3  of patient-derived cytokine-induced killer (CIK) cells against autologous bone sarcoma and STS, incl
4 b and ramucirumab), but 2 were not (adjuvant CIK cells and sorafenib plus hepatic arterial infusion w
5                                              CIK cells are cytotoxic against autologous and allogenei
6                     Cytokine-induced killer (CIK) cells are ex vivo-expanded T lymphocytes expressing
7 These cells, termed cytokine-induced killer (CIK) cells, are composed primarily of T cells, and the p
8 CSCs, supporting the clinical development of CIK cells as a novel class of immunotherapy for use in s
9             The mice who received autologous CIK cells at 4 weeks had either no tumor (5) or small tu
10 umors (5), whereas all 10 mice that received CIK cells at week 8 developed lymphomas; however, these
11 To test the in vivo activity of the expanded CIK cells, CML was engrafted into severe combined immuno
12         We evaluated different properties of CIK cells compared with conventional T cells, demonstrat
13    Further in vivo analyses established that CIK cells could infiltrate tumors and that tumor growth
14                      Intravenous infusion of CIK cells delayed autologous tumor growth in immunodefic
15 lls expanded from 21 patients, we found that CIK cells efficiently killed allogeneic and autologous s
16                                        Using CIK cells expanded from 21 patients, we found that CIK c
17                                              CIK cells from all patients showed cytotoxicity against
18                                   Allogeneic CIK cells from normal donors also suppressed CML colony
19          Due to these properties, allogeneic CIK cells had reduced expansion and caused less tissue d
20                             We conclude that CIK cells have the potential to separate graft-versus-tu
21 lls, demonstrating a slower division rate of CIK cells, higher susceptibility to apoptosis, persisten
22 making regarding the application of adjuvant CIK cell immunotherapy.
23 enefits of adjuvant cytokine-induced killer (CIK) cell immunotherapy for hepatocellular carcinoma (HC
24  showed that adoptive transfer of allogeneic CIK cells in a murine model caused minimal graft-versus-
25 icking and survival of luciferase-expressing CIK cells in an allogeneic bone marrow transplant model.
26 entional T cells that induced GVHD; however, CIK cells infiltrated GVHD target tissues much less and
27 2 out of 13 mice who received the autologous CIK cells (P = .02).
28 s in the 10 control mice who did not receive CIK cells (P = .03).
29 differentiated into cytokine-induced killer (CIK) cells.RESULTSThe cellular product was produced succ
30                In four patients the expanded CIK cells suppressed colony growth of autologous CML bla
31 ctions of the survival benefit from adjuvant CIK cell treatment after hepatectomy.
32  predictions of survival benefit of adjuvant CIK cell treatment for HCC patients.
33                                              CIK cells were expanded from PBMNCs from 13 patients wit
34          After 4 weeks, 4 x 10(7) autologous CIK cells were injected intravenously by tail vein injec
35          The initial trafficking patterns of CIK cells were similar to conventional T cells that indu
36                        This study shows that CIK cells, which are Ph chromosome-negative, can be expa
37                              Preinfection of CIK cells with modified vaccinia virus resulted in a pro
38 or cell population [cytokine-induced killer (CIK) cells] with an oncolytic viral therapy to achieve d